📣 VC round data is live. Check it out!
- Public Comps
- Allurion
Allurion Valuation Multiples
Discover revenue and EBITDA valuation multiples for Allurion and similar public comparables like Spineguard, Renalytix, Vidavo, Scandinavian ChemoTech and more.
Allurion Overview
About Allurion
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Founded
2023
HQ

Employees
137
Website
Financials (LTM)
EV
$34M
Valuation Multiples
Start free trialAllurion Financials
Allurion reported last 12-month revenue of $14M.
Revenue (LTM)
Allurion P&L
In the most recent fiscal year, Allurion reported revenue of - and net income of -.
Financial data powered by Morningstar, Inc.
Allurion Stock Performance
Allurion has current market cap of $10M, and enterprise value of $34M.
Market Cap Evolution
Allurion's stock price is $0.70.
Allurion share price decreased by 70.1% in the last year.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $34M | $10M | 0.0% | - | 4.1% | -70.1% | - |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAllurion Valuation Multiples
Allurion trades at 2.4x EV/Revenue multiple.
EV / Revenue (LTM)
Allurion Financial Valuation Multiples
As of June 2, 2026, Allurion has market cap of $10M and EV of $34M.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Allurion Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Allurion Margins & Growth Rates
Allurion Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Allurion Competitors
Allurion competitors include Spineguard, Renalytix, Vidavo, Scandinavian ChemoTech, Lifecare, Nestmedic, Wellgistics Health, Media Lab, Scandinavian Medical and iXensor.
Most Allurion public comparables operate across Medical Devices, Health Data & Analytics, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.3x | 2.1x | (8.0x) | (12.5x) | |||
| 3.4x | 3.4x | (0.5x) | - | |||
| 3.8x | - | 9.9x | - | |||
| 7.3x | 6.0x | (21.9x) | (33.5x) | |||
| 984.9x | - | (1.0x) | (1.1x) | |||
| 33.2x | - | (10.5x) | - | |||
| 1.6x | - | (0.4x) | - | |||
| 4.1x | - | 13.3x | - | |||
This data is available for Pro users. Sign up to see all Allurion competitors and their valuation data. Start Free Trial | ||||||
Allurion VC Funding History
Before going public, Allurion raised $123M in total equity funding, across 7 rounds.
Allurion Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Allurion
| When was Allurion founded? | Allurion was founded in 2023. |
| Where is Allurion headquartered? | Allurion is headquartered in United States. |
| How many employees does Allurion have? | As of today, Allurion has over 137 employees. |
| Who is the CEO of Allurion? | Allurion's CEO is Shantanu Gaur. |
| Is Allurion publicly listed? | Yes, Allurion is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Allurion? | Allurion trades under ALUR ticker. |
| When did Allurion go public? | Allurion went public in 2023. |
| Who are competitors of Allurion? | Allurion main competitors include Spineguard, Renalytix, Vidavo, Scandinavian ChemoTech, Lifecare, Nestmedic, Wellgistics Health, Media Lab, Scandinavian Medical, iXensor. |
| What is the current market cap of Allurion? | Allurion's current market cap is $10M. |
| What is the current revenue of Allurion? | Allurion's last 12 months revenue is $14M. |
| What is the current revenue growth of Allurion? | Allurion revenue growth (NTM/LTM) is (5%). |
| What is the current EV/Revenue multiple of Allurion? | Current revenue multiple of Allurion is 2.4x. |
| Is Allurion profitable? | No, Allurion is not profitable. |
| How many companies Allurion has acquired to date? | Allurion hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Allurion has invested to date? | Allurion hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Allurion
Lists including Allurion
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.